Our Solution - The TARGET Model

In today’s model, multiple stakeholders work in silos to generate similar types of data. With TARGET’s unique approach, the study design is disease focused, not drug-specific. This allows for a continuous acquisition of natural history and outcomes data as new drugs enter the market while providing an opportunity to evaluate the impact of changing management paradigms to the level of the individual patient.